Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
This study has been completed.
Information provided by (Responsible Party):
Gary Kinasewitz, University of Oklahoma
First received: June 24, 2009
Last updated: April 5, 2012
Last verified: April 2012
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.
The investigators plan to measure these factors prior to and after bronchoscopy.
||Observational Model: Case Control
Time Perspective: Prospective
||Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.
Secondary Outcome Measures:
- Volume of blood loss during the procedure [ Time Frame: 1 day ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2010 (Final data collection date for primary outcome measure)
Comparison between individuals with and without pulmonary malignancy
This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.
|Ages Eligible for Study:
||18 Years to 80 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Patients from the VAMC in Oklahoma city
- Any patient scheduled to undergo bronchoscopy
- Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000
- Patients not scheduled to undergo bronchoalveolar lavage (BAL)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00929565
|VA Medical Center
|Oklahoma City, Oklahoma, United States, 73104 |
University of Oklahoma
||Jijo John, MD
||University of Oklahoma
||Gary Kinasewitz, Principal Investigator, University of Oklahoma
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 24, 2009
||April 5, 2012
Keywords provided by Gary Kinasewitz, University of Oklahoma:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 25, 2017
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action